

## **Closure of USFDA inspection at Zydus' oncology injectable plant at Ahmedabad**

*Ahmedabad, India, June 18, 2025*

We wish to inform that the US, Food and Drug Administration (USFDA) conducted a GMP follow-up inspection at the company's oncology injectable site situated at SEZ 1, near Matoda, Ahmedabad. The inspection was conducted from 9<sup>th</sup> of June to 18<sup>th</sup> of June 2025.

The inspection is closed with 2 observations and none of them were related to data integrity. The Company will closely work with the USFDA to address and respond to the observations in an expeditious manner.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.

###



**PRESS  
RELEASE**

For further information please contact :  
**The Corporate Communications Department**

**Zydus Lifesciences Limited**

Regd. Office : 'Zydus Corporate Park',  
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),  
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382  
481, Gujarat, India. | Phone : +91-79-71800000,  
+91-79-48040000 | website : [www.zyduslife.com](http://www.zyduslife.com)  
CIN : L24230GJ1995PLC025878